Abstract: The present invention relates to a use of mycophenolate mofetil or a pharmaceutically acceptable salt thereof in the manufacture of a medicament against influenza virus. The present invention also relates to a use of mycophenolate mofetil or a pharmaceutically acceptable salt thereof in the manufacture of a medicament against drug-resistant influenza virus strains. The present invention is further related to a method for treating influenza in a subject, comprising administering to said subject an effective amount of mycophenolate mofetil or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a use of mycophenolate mofetil or a pharmaceutically acceptable salt thereof in the manufacture of a medicament against influenza virus. The present invention also relates to a use of mycophenolate mofetil or a pharmaceutically acceptable salt thereof in the manufacture of a medicament against drug-resistant influenza virus strains. The present invention is further related to a method for treating influenza in a subject, comprising administering to said subject an effective amount of mycophenolate mofetil or a pharmaceutically acceptable salt thereof.

Abstract: For the reported resveratrol analogs, the (E)-stilbene core structure is either maintained intact or only slightly modified. We use a different approach and introduced a novel heterocyclic benzothiazolium moiety into the (E)-stilbene core to form a series of novel resveratrol analogs for treating angiogenic- and/or inflammation-related disorders.

Abstract: The present invention provides a pharmaceutical composition and method for treating or preventing influenza virus infection in a subject comprising administering the subject with a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of compounds provided in this invention. In addition, the prevent invention provides new compounds for treating or preventing influenza virus infection.

Abstract: Disclosed are an Schisandrae fructus extract for inhibition or prevention of influenza and its application, wherein the Schisandrae fructus extract is obtained by water, methanol, or ethanol extraction process and the extract comprises compounds such as schisandrone, benzoylgomisin P, wulignan A1, epigomisin O, epiwulignan A1, and tigloylgomisin P. The extracts and purified compounds of Schisandrae fructus has anti-influenza virus H1N1 and H1N1-TR (a Tamiflu drug resistant virus strain) activities, therefore the extracts and the purified compounds of Schisandrae fructus can be applied as an inhitibory agent of a pharmaceutical composition for treatment or prevention agent for influenza infection.

Abstract: Disclosed are an Schisandrae fructus extract for inhibition or prevention of influenza and its application, wherein the Schisandrae fructus extract is obtained by water, methanol, or ethanol extraction process and the extract comprises compounds such as schisandrone, benzoylgomisin P, wulignan A1, epigomisin O, epiwulignan A1, and tigloylgomisin P. The extracts and purified compounds of Schisandrae fructus has anti-influenza virus H1N1 and H1N1-TR (a Tamiflu drug resistant virus strain) activities, therefore the extracts and the purified compounds of Schisandrae fructus can be applied as an inhitibory agent of a pharmaceutical composition for treatment or prevention agent for influenza infection.

Abstract: Disclosed are 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives and manufactures thereof. The 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives are presented by formula (I): wherein R1 group is H, CH3, or C2H5; R2 group is H, or Br; R3 group is CH3, or C3H7; and R4 group is H, or C(?NH)—NH2. 4,5-diamino-3-halo-2-hydroxybenzoic acid derivatives provided here were non-toxic to MDCK cells, particularly compounds 6a, 6b, 6c, 6e, 6f, 7a, 7b and 8 had better anti-H1N1 activity. In the future, these compounds can be used to focus on viral neuraminidases as targets to develop effective anti-influenza drugs.

Abstract: The invention provides a herbal extract having anti-influenza virus activity, by extracting Sophora flavescens Ait, Thesium chinense Turcz, licorice, or mixture thereof with solvent.

Abstract: A series of isoxazole derivatives and methods of treating immune-mediated diseases by isoxazole derivatives are described.

Abstract: A series of isoxazole derivatives and methods of suppressing, inhibiting, or preventing disorders mediated by nitric oxide (NO) and/or proinflammatory cytokines, such as TNF-? (tumor necrosis factor alpha), IL-1 (interlukin-1), and IL-6, are described.

Abstract: Methods of treating cancer employing isoxazole derivatives are described. Compounds and methods of using these compounds for isolating and/or detecting binding proteins, which may be indicative of a disease, are also described.

Abstract: A series of isoxazole derivatives and methods of suppressing, inhibiting, or preventing disorders mediated by nitric oxide (NO) and/or proinflammatory cytokines, such as TNF-? (tumor necrosis factor alpha), IL-1 (interlukin-1), and IL-6, are described.

Abstract: Methods of treating cancer employing isoxazole derivatives are described. Compounds and methods of using these compounds for isolating and/or detecting binding proteins, which may be indicative of a disease, are also described.

Abstract: Simple and efficient total syntheses of flavonoids including baicalein, oroxylin A and wogonin are described herein. Simultaneous syntheses of oroxylin A and wogonin are also described.

Abstract: Novel leflunomide analogs were synthesized and evaluated in-vivo. Based on the in-vivo studies, these analogs are surprisingly effective for treating rheumatoid arthritis.

Abstract: In the invention of novel nonsteroidal antiinflammatory compounds the title novel triazole compounds, were synthesized from carboxylic acids, 2,5-acetonylacetone, or isoniazid, respectively. To give 4H-1,2,4-triazol-3-thiols. Treatment of 4H-1,2,4-tri-azol-3-thiols with methyl chloroacetate or methyl .alpha.-chloropropionate resulted in the formation of compounds I-VI. The antiinflammatory activity of those new triazole compounds were determined by the carrageenin-induced edema method and they showed potent activity. In the dosage form studies those compounds of formula I-VI were added suituble vehicleo to prepare antiinflammatory agents.